ACFN vs LGL

ACFN's deterministic health scorecard reveals significant red flags: a weak Piotroski F-Score of 3/9 indicates deteriorating financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a high intrinsic value estimate of $18.62 and a Graham Number of $14.04, the stock trades at $19.04, reflecting a premium that is not justified by current fundamentals. The company exhibits severe revenue and earnings contraction (-32.6% and -79.9% YoY), with a history of large negative earnings surprises and inconsistent beat rates. Technical and insider signals are neutral to bearish, and analyst coverage is absent, underscoring a lack of institutional confidence.

LGL exhibits significant fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and a current price ($7.28) that trades at a massive premium to both its Graham Number ($4.19) and Intrinsic Value ($0.77). While the company maintains an exceptionally clean balance sheet with virtually no debt and extreme liquidity, its operational efficiency is poor, evidenced by very low ROE (1.74%) and a dismal earnings track record. The stock appears to be priced for growth that is not supported by its current 5.4% revenue growth or its consistent failure to meet earnings estimates.